Tero Aittokallio

Identifying prognostically relevant subsets of endometrial cancer using unsupervised clustering of immunohistochemical staining data (2013)

Virchows Archiv

Huvila J, Laajala D, Edqvist PH, Talve L, Grenman S, Ponten F, Aittokallio T, Carpen O, Auranen A

(O2 Muu julkaisu )

Parallel Feature Selection for Regularized Least-Squares (2013)

Lecture Notes in Computer Science

Sebastian Okser, Antti Airola, Tero Aittokallio, Tapio Salakoski, Tapio Pahikkala

(Vertaisarvioitu artikkeli konferenssijulkaisussa (A4))

Development of a drug sensitivity testing pipeline towards the establishment of precision medicine for ovarian cancer (2013)

Clinical Cancer Research

Hirasawa A, Murum,Gi A, Yadav B, Mpindi JP, Mariliina A, Aittokallio T, Wennerberg K, Aoki D, Kallioniemi O

(O2 Muu julkaisu )

Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice (2013)

Cell Death and Disease

Kakkola L, Denisova OV, Tynell J, Viiliainen J, Ysenbaert T, Matos RC, Nagaraj A, Ohman T, Kuivanen S, Paavilainen H, Feng L, Yadav B, Julkunen I, Vapalahti O, Hukkanen V, Stenman J, Aittokallio T, Verschuren EW, Ojala PM, Nyman T, Saelens X, Dzeyk K, Kainov DE

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways (2013)

PLoS Computational Biology

Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, Aittokallio T

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Predicting drug-target interactions through integrative analysis of chemogenetic assays in yeast (2013)

Molecular BioSystems

Marja A Heiskanen, Tero Aittokallio

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Functional drug sensitivity and resistance profiling of AML patient cells defines a disease-specific combination of druggable signal addictions (2013)

Cancer Research

Pemovska T, Yadav B, Karjalainen R, Kulesskiy E, Kontro M, Majumder MM, Turunen L, Lindenschmidt I, Lehto A, Knowles J, Heckman C, Porkka K, Aittokallio T, Kallioniemi O, Wennerberg K

(O2 Muu julkaisu )

Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance (2012)

Cancer Research

Pemovska T, Kylesskiy E, Kontro M, Szwajda A, Karjalainen R, Majumder MM, Malani D, Bespalov MM, Eldfors S, Elonen E, Knowles J, Murumagi A, Mpindi JP, Edgren H, Venkata NPK, Turunen L, Mustjoki S, Wolf M, Yadav B, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K

(O2 Muu julkaisu )

A multilevel layout algorithm for visualizing physical and genetic interaction networks, with emphasis on their modular organization (2012)

BioData Mining

Tuikkala J, Vähämaa H, Salmela P, Nevalainen OS, Aittokallio T

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns (2012)

Cancer Research

Malani D, Pemovska T, Kontro M, Murumagi A, Kulesskiy E, Yadav B, Bespalov M, Eldfors S, Elonen E, Karjalainen R, Knowles JKC, Majumder MM, Mpindi JP, Edgren H, Szwajda A, Venkata NPK, Turunen L, Mustjoki S, Wolf M, Aittokallio T, Heckman CA, Porkka K, Wennerberg K, Kallioniemi O

(O2 Muu julkaisu )

Ota yhteyttä

Linkit

Julkaisut

Järjestä:

Identifying prognostically relevant subsets of endometrial cancer using unsupervised clustering of immunohistochemical staining data (2013)

Parallel Feature Selection for Regularized Least-Squares (2013)

Development of a drug sensitivity testing pipeline towards the establishment of precision medicine for ovarian cancer (2013)

Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice (2013)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways (2013)

Predicting drug-target interactions through integrative analysis of chemogenetic assays in yeast (2013)

Functional drug sensitivity and resistance profiling of AML patient cells defines a disease-specific combination of druggable signal addictions (2013)

Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance (2012)

A multilevel layout algorithm for visualizing physical and genetic interaction networks, with emphasis on their modular organization (2012)

Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns (2012)